Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers

K. Szepeshazi, Andrew V Schally, K. Groot, P. Armatis, G. Halmos, F. Hebert, B. Szende, J. L. Varga, M. Zarandi

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Insulin-like growth factors (IGFs) I and II are implicated in progression of various tumours including colorectal carcinomas. To interfere with the production of IGFs, we treated male nude mice bearing xenografts of HT-29 human colon cancer with various potent growth hormone-releasing hormone (GH-RH) antagonists. Twice daily injections of antagonist MZ-4-71, 10 μg intraperitoneally or 5 μg subcutaneously (s.c.) resulted in a significant 43-45% inhibition of tumour growth. Longer acting GH-RH antagonists, MZ-5-156 and JV-1-36 given once daily at doses of 20 μg s.c. produced a 43-58% decrease in volume and weight of cancers. Histological analyses of HT-29 cancers demonstrated that both a decreased cell proliferation and an increased apoptosis contributed to tumour inhibition. GH-RH antagonists did not change serum IGF-I or IGF-II levels, but significantly decreased IGF-II concentration and reduced mRNA expression for IGF-II in tumours. In vitro studies showed that MT-29 cells produced and secreted IGF-II into the medium, and addition of MZ-5-156 dose-dependently decreased IGF-II production by about 40% as well as proliferation of MT-29 cells. Our studies demonstrate that GH-RH antagonists inhibit growth of HT-29 human colon cancers in vivo and in vitro. The effect of GH-RH antagonists may be mediated through a reduced production and secretion of IGF-II by cancer cells. (C) 2000 Cancer Research Campaign.

Original languageEnglish
Pages (from-to)1724-1731
Number of pages8
JournalBritish Journal of Cancer
Volume82
Issue number10
StatePublished - May 10 2000
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Insulin-Like Growth Factor II
Hormone Antagonists
Colonic Neoplasms
Growth
Neoplasms
Insulin-Like Growth Factor I
Somatomedins
Heterografts
Nude Mice
Colorectal Neoplasms
Cell Proliferation
Apoptosis
Weights and Measures
Messenger RNA
Injections
Serum

Keywords

  • AgNOR
  • Apoptosis
  • Colon cancer
  • GH-RH antagonists
  • IGF-I
  • IGF-I receptor
  • IGF-II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Szepeshazi, K., Schally, A. V., Groot, K., Armatis, P., Halmos, G., Hebert, F., ... Zarandi, M. (2000). Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. British Journal of Cancer, 82(10), 1724-1731.

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. / Szepeshazi, K.; Schally, Andrew V; Groot, K.; Armatis, P.; Halmos, G.; Hebert, F.; Szende, B.; Varga, J. L.; Zarandi, M.

In: British Journal of Cancer, Vol. 82, No. 10, 10.05.2000, p. 1724-1731.

Research output: Contribution to journalArticle

Szepeshazi, K, Schally, AV, Groot, K, Armatis, P, Halmos, G, Hebert, F, Szende, B, Varga, JL & Zarandi, M 2000, 'Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers', British Journal of Cancer, vol. 82, no. 10, pp. 1724-1731.
Szepeshazi, K. ; Schally, Andrew V ; Groot, K. ; Armatis, P. ; Halmos, G. ; Hebert, F. ; Szende, B. ; Varga, J. L. ; Zarandi, M. / Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. In: British Journal of Cancer. 2000 ; Vol. 82, No. 10. pp. 1724-1731.
@article{6cd582317e0c42fbb7ef0698e7f34984,
title = "Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers",
abstract = "Insulin-like growth factors (IGFs) I and II are implicated in progression of various tumours including colorectal carcinomas. To interfere with the production of IGFs, we treated male nude mice bearing xenografts of HT-29 human colon cancer with various potent growth hormone-releasing hormone (GH-RH) antagonists. Twice daily injections of antagonist MZ-4-71, 10 μg intraperitoneally or 5 μg subcutaneously (s.c.) resulted in a significant 43-45{\%} inhibition of tumour growth. Longer acting GH-RH antagonists, MZ-5-156 and JV-1-36 given once daily at doses of 20 μg s.c. produced a 43-58{\%} decrease in volume and weight of cancers. Histological analyses of HT-29 cancers demonstrated that both a decreased cell proliferation and an increased apoptosis contributed to tumour inhibition. GH-RH antagonists did not change serum IGF-I or IGF-II levels, but significantly decreased IGF-II concentration and reduced mRNA expression for IGF-II in tumours. In vitro studies showed that MT-29 cells produced and secreted IGF-II into the medium, and addition of MZ-5-156 dose-dependently decreased IGF-II production by about 40{\%} as well as proliferation of MT-29 cells. Our studies demonstrate that GH-RH antagonists inhibit growth of HT-29 human colon cancers in vivo and in vitro. The effect of GH-RH antagonists may be mediated through a reduced production and secretion of IGF-II by cancer cells. (C) 2000 Cancer Research Campaign.",
keywords = "AgNOR, Apoptosis, Colon cancer, GH-RH antagonists, IGF-I, IGF-I receptor, IGF-II",
author = "K. Szepeshazi and Schally, {Andrew V} and K. Groot and P. Armatis and G. Halmos and F. Hebert and B. Szende and Varga, {J. L.} and M. Zarandi",
year = "2000",
month = "5",
day = "10",
language = "English",
volume = "82",
pages = "1724--1731",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers

AU - Szepeshazi, K.

AU - Schally, Andrew V

AU - Groot, K.

AU - Armatis, P.

AU - Halmos, G.

AU - Hebert, F.

AU - Szende, B.

AU - Varga, J. L.

AU - Zarandi, M.

PY - 2000/5/10

Y1 - 2000/5/10

N2 - Insulin-like growth factors (IGFs) I and II are implicated in progression of various tumours including colorectal carcinomas. To interfere with the production of IGFs, we treated male nude mice bearing xenografts of HT-29 human colon cancer with various potent growth hormone-releasing hormone (GH-RH) antagonists. Twice daily injections of antagonist MZ-4-71, 10 μg intraperitoneally or 5 μg subcutaneously (s.c.) resulted in a significant 43-45% inhibition of tumour growth. Longer acting GH-RH antagonists, MZ-5-156 and JV-1-36 given once daily at doses of 20 μg s.c. produced a 43-58% decrease in volume and weight of cancers. Histological analyses of HT-29 cancers demonstrated that both a decreased cell proliferation and an increased apoptosis contributed to tumour inhibition. GH-RH antagonists did not change serum IGF-I or IGF-II levels, but significantly decreased IGF-II concentration and reduced mRNA expression for IGF-II in tumours. In vitro studies showed that MT-29 cells produced and secreted IGF-II into the medium, and addition of MZ-5-156 dose-dependently decreased IGF-II production by about 40% as well as proliferation of MT-29 cells. Our studies demonstrate that GH-RH antagonists inhibit growth of HT-29 human colon cancers in vivo and in vitro. The effect of GH-RH antagonists may be mediated through a reduced production and secretion of IGF-II by cancer cells. (C) 2000 Cancer Research Campaign.

AB - Insulin-like growth factors (IGFs) I and II are implicated in progression of various tumours including colorectal carcinomas. To interfere with the production of IGFs, we treated male nude mice bearing xenografts of HT-29 human colon cancer with various potent growth hormone-releasing hormone (GH-RH) antagonists. Twice daily injections of antagonist MZ-4-71, 10 μg intraperitoneally or 5 μg subcutaneously (s.c.) resulted in a significant 43-45% inhibition of tumour growth. Longer acting GH-RH antagonists, MZ-5-156 and JV-1-36 given once daily at doses of 20 μg s.c. produced a 43-58% decrease in volume and weight of cancers. Histological analyses of HT-29 cancers demonstrated that both a decreased cell proliferation and an increased apoptosis contributed to tumour inhibition. GH-RH antagonists did not change serum IGF-I or IGF-II levels, but significantly decreased IGF-II concentration and reduced mRNA expression for IGF-II in tumours. In vitro studies showed that MT-29 cells produced and secreted IGF-II into the medium, and addition of MZ-5-156 dose-dependently decreased IGF-II production by about 40% as well as proliferation of MT-29 cells. Our studies demonstrate that GH-RH antagonists inhibit growth of HT-29 human colon cancers in vivo and in vitro. The effect of GH-RH antagonists may be mediated through a reduced production and secretion of IGF-II by cancer cells. (C) 2000 Cancer Research Campaign.

KW - AgNOR

KW - Apoptosis

KW - Colon cancer

KW - GH-RH antagonists

KW - IGF-I

KW - IGF-I receptor

KW - IGF-II

UR - http://www.scopus.com/inward/record.url?scp=0034110139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034110139&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 1724

EP - 1731

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -